Literature DB >> 26660106

A case of Brooke-Spiegler syndrome with a novel mutation in the CYLD gene in a patient with aggressive non-Hodgkin's lymphoma.

F Hunstig1, S Schulz2, I Nieten3, U Froster4, C Boltze5, S Schliemann6, A Hochhaus3, P La Rosée3.   

Abstract

PURPOSE: Brooke-Spiegler syndrome (BSS, familial cylindromatosis) is a rare hereditary disease characterized by multiple tumors of the skin appendages predominantly located in the head and neck region, such as cylindromas, trichoepitheliomas, or spiradenomas. It is caused by an autosomal dominant mutation in the CYLD gene, mapped on chromosome 16q12-13. Association with secondary malignant neoplasms has been reported. Until now 51 different mutations in 73 families have been reported; 41 % of them constitute frameshift mutations, resulting in an interruption of the expression of the gene product CYLD. CYLD is a deubiquitinating enzyme and plays an important role in (NF)-κB pathway signaling, a central pathway for apoptosis regulation. Mutation-induced loss of function leads to constitutive activation of NF-κB.
METHODS: Here, we report the case of a 48-year-old female patient diagnosed with an abdominal aggressive non-Hodgkin's lymphoma. The patient presented with multiple cylindromas of the capillitium. The patient's mother also has a mild form of late-onset cylindromas. Due to the typical clinical features indicating BSS, genotyping from peripheral blood was performed. A c.2465insAACA mutation in exon 17 of the CYLD gene, leading to a frameshift, was detected in the patient and in the patient's mother. RESULTS/
CONCLUSIONS: This is the first description of this hereditary mutation in exon 17 of the CYLD gene. There have been several reports on patients with CYLD mutations and different types of malignancies. However, a coincidence with aggressive non-Hodgkin's lymphoma has not been reported yet.

Entities:  

Keywords:  Brooke–Spiegler syndrome; CYLD gene; Case report; Non-Hodgkin’s lymphoma; Novel mutation

Mesh:

Substances:

Year:  2015        PMID: 26660106     DOI: 10.1007/s00432-015-2079-y

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  13 in total

1.  Spiradenocylindroma of the kidney: clinical and genetic findings suggesting a role of somatic mutation of the CYLD1 gene in the oncogenesis of an unusual renal neoplasm.

Authors:  Philipp Ströbel; Andreas Zettl; Zhou Ren; Petr Starostik; Hubertus Riedmiller; Stephan Störkel; Hans Konrad Müller-Hermelink; Alexander Marx
Journal:  Am J Surg Pathol       Date:  2002-01       Impact factor: 6.394

2.  Reduced expression of CYLD in human colon and hepatocellular carcinomas.

Authors:  Claus Hellerbrand; Elisabeth Bumes; Frauke Bataille; Wolfgang Dietmaier; Ramin Massoumi; Anja K Bosserhoff
Journal:  Carcinogenesis       Date:  2006-06-13       Impact factor: 4.944

Review 3.  Aggressive lymphomas.

Authors:  Georg Lenz; Louis M Staudt
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

4.  Rare occurrence of biallelic CYLD gene mutations in classical Hodgkin lymphoma.

Authors:  Annette Schmidt; Roland Schmitz; Maciej Giefing; Jose Ignacio Martin-Subero; Stefan Gesk; Inga Vater; Anne Massow; Ewerton Maggio; Markus Schneider; Martin-Leo Hansmann; Reiner Siebert; Ralf Küppers
Journal:  Genes Chromosomes Cancer       Date:  2010-09       Impact factor: 5.006

5.  CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members.

Authors:  Eirini Trompouki; Eudoxia Hatzivassiliou; Theodore Tsichritzis; Hannah Farmer; Alan Ashworth; George Mosialos
Journal:  Nature       Date:  2003-08-14       Impact factor: 49.962

6.  Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells.

Authors:  Nobuyuki Kikuno; Hiroaki Shiina; Shinji Urakami; Ken Kawamoto; Hiroshi Hirata; Yuichiro Tanaka; Shahana Majid; Mikio Igawa; Rajvir Dahiya
Journal:  Int J Cancer       Date:  2008-08-01       Impact factor: 7.396

Review 7.  Targeting the ubiquitin-proteasome system for cancer therapy.

Authors:  Yili Yang; Jirouta Kitagaki; Honghe Wang; De-Xing Hou; Alan O Perantoni
Journal:  Cancer Sci       Date:  2008-11-24       Impact factor: 6.716

8.  Conventional and array-based comparative genomic hybridization analyses of novel cell lines harboring HPV18 from glassy cell carcinoma of the uterine cervix.

Authors:  Yasuo Hirai; Yasutaka Kawamata; Nobuhiro Takeshima; Reiko Furuta; Tomoyuki Kitagawa; Tokuichi Kawaguchi; Katsuhiko Hasumi; Sachiko Sugai; Tetsuo Noda
Journal:  Int J Oncol       Date:  2004-04       Impact factor: 5.650

9.  Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.

Authors:  Mara Compagno; Wei Keat Lim; Adina Grunn; Subhadra V Nandula; Manisha Brahmachary; Qiong Shen; Francesco Bertoni; Maurilio Ponzoni; Marta Scandurra; Andrea Califano; Govind Bhagat; Amy Chadburn; Riccardo Dalla-Favera; Laura Pasqualucci
Journal:  Nature       Date:  2009-05-03       Impact factor: 49.962

Review 10.  Regulation and function of NF-kappaB transcription factors in the immune system.

Authors:  Sivakumar Vallabhapurapu; Michael Karin
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.